Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens. (February 2017)

• Record Type: Journal Article
• Authors: Peng, Pei-Jian; Lv, Bao-Jun; Wang, Zhi-Hui; Liao, Hai; Liu, Yu-Meng; Lin, Zhong; Con, Yun-Yan; Huang, Pei-Yu
• Is Part Of: Therapeutic advances in medical oncology. Volume 9:Number 2(2017:Mar.)
• Page Start: 68
• Page End: 74
• Publication Date: 2017-02
• Subjects: chemotherapy -- nasopharyngeal carcinoma -- nedaplatin -- S-1; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/1758834016675099
• Languages: English
• ISSNs: 1758-8340

Abstract

Background: In this multi-institutional prospective study, we aimed to assess the safety and efficacy of nedaplatin plus S-1 (NS) chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when platinum-containing regimens failed. Methods: A total of 52 recurrent and metastatic NPC patients who previously received, but failed with platinum-containing chemotherapy, had oral S-1 chemotherapy (twice daily from the first day to the fourteenth day) and nedaplatin (80 mg/ m 2, day 1) every 3 weeks. The body surface area (BSA) decided the dose of S-1: 40 mg twice a day when BSA < 1.25 m 2 ; 50 mg twice daily when 1.25 m 2 ⩽ BSA < 1.5 m 2 ; and 60 mg twice daily when BSA ⩾ 1.5 m 2 . Results: Treatment was well tolerated. The main hematological adverse event was neutropenia. Five patients (9.6%) had grade 3 neutropenia. Three patients were found with grade 3 anemia (5.8%). One patient was found with grade 3 thrombocytopenia (1.9%). No patient was found with grade 3 or 4 nonhematological toxicity. The rates of complete response, partial response and overall response were 3.8%, 38.5% and 42.3%, respectively. Median time to progression was 6.2 months and median survival was 14.6 months. The rates of 1-year survival and 2-year survival were 63% and 27%, respectively. Conclusions: NS chemotherapy provides a satisfactory and safe clinical activity for patients with recurrent and metastatic NPC after platinum-containing chemotherapy failed.